The company has generated a portfolio of anti-CD47 antibodies that have the potential to surmount multiple checkpoints by which cancer evades the immune system. These antibodies are protected by a strong, multilayered intellectual property estate that includes composition-of-matter and uses of humanized anti-CD47 antibodies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/16/16 | $86,000,000 | Series A |
Novo Ventures RiverVest Venture Partners Roche Venture Fund SR One | undisclosed |
